Press Releases

27 September 2016 (Nairobi, Kenya) – TB Alliance is proud to announce the launch of new medicines for childhood tuberculosis

“TB Alliance welcomes the UN’s Political Declaration on Antimicrobial Resistance (AMR), which is an important step in mobilizing the political and

This piece first appeared at SciDev.Net. Access the original story here. MANILA (August 25, 2016) Several countries are in a race to make

NEW YORK AND OSAKA (June 21, 2016) — TB Alliance and Takeda Pharmaceutical Company Limited (Headquarters: Osaka, Japan; “Takeda”) announced

NEW YORK AND GENEVA (April 20, 2016) – TB Alliance and the Medicines Patent Pool (MPP)  today announced a Memorandum

NEW YORK, NY (March 11, 2016)—TB Alliance has announced that it has stopped the clinical development program for the tuberculosis

Medication simplifies and improves treatment for 1 million children with TB Medicines come in dispersible fixed-dose combinations at the correct

TB Alliance and its partners announced the start of a clinical trial of a new regimen to treat extensively drug-resistant

TB Alliance has announced a new partnership with the U.S. Fund for UNICEF that will dramatically increase the scope and

Critical Path to TB Drug Regimens (CPTR), an initiative that brings together the world’s leading pharmaceutical companies, product development sponsors,